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Available online 15 May 2017Despite benefits of prenatal in utero repair of myelomeningocele, a severe type of spina bifida aperta, many of
these patients will still suffer mild to severe impairment. One potential source of stem cells for new regenerative
medicine-based therapeutic approaches for spinal cord injury repair is neural progenitor cells (NPCs) in cerebro-
spinalfluid (CSF). To this aim,we extracted CSF from the cyst surrounding the exposed neural placode during the
surgical repair of myelomeningocele in 6 fetuses (20 to 26 weeks of gestation). In primary cultured CSF-derived
cells, neurogenic properties were confirmed by in vitro differentiation into various neural lineage cell types, and
NPCmarkers expression (TBR2, CD15, SOX2)were detected by immunofluorescence and RT-PCR analysis. Differ-
entiation into three neural lineages was corroborated by arbitrary differentiation (depletion of growths factors)
or explicit differentiation as neuronal, astrocyte, or oligodendrocyte cell types using specific induction mediums.
Differentiated cells showed the specific expression of neural differentiation markers (βIII-tubulin, GFAP, CNPase,
oligo-O1). Inmyelomeningocele patients, CSF-derived cells could become a potential source of NPCswith neuro-
genic capacity. Our findings support the development of innovative stem-cell-based therapeutics by autologous
transplantation of CSF-derived NPCs in damaged spinal cords, such asmyelomeningocele, thus promoting neural
tissue regeneration in fetuses.






Human primary cell cultures
Fetal therapy1. Introduction
Myelomeningocele is a severe type of spina bifida that represents
one of the most debilitating birth defects in humans (Copp et al.,
2003; Copp and Greene, n.d.; Dias and McLone, 1993; Dias, 1999;
Hunt, 1990; Lary and Edmonds, 1996; Meuli et al., 1997), with an esti-
mated incidence of 3.3 in 10,000 live births. Myelomeningocele harshly
affects both spinal cord and encephalic structures during gestation (Lary
and Edmonds, 1996) resulting in disabilities that include paraplegia,
skeletal deformities, hydrocephalus, hindbrain herniation, impaired
mental development, and fecal, urinary, and sexual dysfunctionn Fetal Surgery for Congenital
ular and Molecular Therapy,
Burnet Avenue, 45229-3039
. This is an open access article under(Dias and McLone, 1993; Dias, 1999; Hunt, 1990). A deficiency on
primary neurulation leads to a deficient neural tube closure and
myelomeningocele formation (Copp et al., 2003; Dias, 1999), which
then induces the progressive neurodegeneration of the exposed spinal
cord during pregnancy (Meuli et al., 1997). In humans, the two most
common neural tube defects are myelomeningocele and myelocele;
neural tissues are surrounded by a thin cystic sac in the former (spina
bifida cystica) or exposed directly to the amniotic fluid in the latter
(Copp and Greene, n.d). The myelomeningocele cyst around the ex-
posed neural tissue contains CSF. When damaged or perforated during
pregnancy, these contents can be released toward the amniotic space
(Meuli and Moehrlen, 2014).
Existing treatments for myelomeningocele repair consist of pre- or
post-natal surgical closure of the defect. Prenatal intervention has
been shown to be more effective than postnatal surgery because it can
prevent or ameliorate sequels (Adzick et al., 2011; Adzick et al., 1998;
Meuli et al., 1997; Meuli et al., 1995). Clearly, in utero repair ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mother and fetus (Adzick et al., 2011; Meuli and Moehrlen, 2014). De-
spite the benefits of surgical repair in preventing further injury, neuro-
logical outcomes remain a critical concern (Gebb et al., 2015) because
of the damage incurred before closure of the defect. In spite of the low
3% perinatal mortality rate and possible benefits of in-utero repair of
myelomeningocele, 36% of patients after surgery hadmild to severe im-
pairment (Danzer et al., 2010; Hisaba et al., 2012). Therefore, new ther-
apeutic approaches concomitant to fetal surgery are needed to improve
locomotive and cognitive functions in these babies.
During the last 10 years, researchers made great efforts toward the
development of neural stem cell-based therapeutic approaches for spi-
nal cord regeneration (Barnabé-Heider and Frisén, 2008; Li and Lepski,
2013; Mothe and Tator, 2013; Parati et al., 2004; Sandner et al., 2012).
Even with CSF's low cellularity (de Graaf et al., 2011), recent studies
have reported that embryonic CSF contains neurogenic growth factors
(Buddensiek et al., 2010; Zappaterra and Lehtinen, 2012). In pre-term
babies with post-hemorrhagic hydrocephalus, CSF samples showed
some circulating cells with neural progenitor properties (Krueger et
al., 2006). Although technical difficulties exist in CSF sampling during
gestation, the findings of neural progenitor cells (NPCs) in CSF strongly
support its potential as an important source of stem cells for the new re-
generative medicine-based therapeutic approaches for spinal cord inju-
ry repair. During prenatal surgical repair of myelomeningocele
(Enriquez et al., 2012; Peiró et al., 2009a; Peiró et al., 2009b; Pellicer et
al., 2007; Ruano et al., 2013a, 2013b), collection of fresh and well-pre-
served CSF samples from the cyst was feasible by gentle aspiration,
thus permitting examination of its properties and cellular composition.
To further this strategy, we evaluated the NPC types in CSF samples
collected from the lumbar cyst that covered the defect in a small sample
of patients undergoing repair of myelomeningocele. We then deter-
mined the neurogenic properties of CSF-derived cells by in vitro charac-
terization and differentiation into various neural lineage cell types.
2. Materials and methods
During the surgical repair of myelomeningocele in 6 fetuses be-
tween 20 and 26 weeks of gestation, CSF samples were extracted from
the cyst surrounding the exposed neural placode. The study was ap-
proved by the IRB Ethics Committees of CCHMC (IRB 2013-5324) and
IRB of the Vall d'Hebron University Hospital (protocol ID: PR(AMI)65/
2013). Patients received detailed information about the experimental
protocol and gave written consent for their participation.
2.1. Human cerebrospinal fluid samples
Before the actual surgical repair of the myelomeningocele, the cyst
was punctured to gently aspirate 1.5–2 ml of CSF using a 5-ml (BD
Luer-Lok™) syringe with 22-gauge detachable needle (Becton Dickin-
son, Franklin Lakes, New Jersey). These samples were then used to es-
tablish the CSF-derived primary cell cultures designated as CSF-fc1 to
fc6: fc1, 2, 3, and 5 (male fetuses of 20, 20, 21, and 25weeks of gestation,
respectively) and fc4 and 6 (female fetuses of 25 and 26weeks of gesta-
tion, respectively).
2.2. Primary cell culture of human CSF-derived stem cells
Immediately after CSF collection, the cell culture was begun under
sterile conditions. First, 1.5–2 ml of CSF were mixed with 15 ml of pro-
liferation medium composed of high glucose Dulbecco's modified
Eagle's medium (DMEM):M-199 medium (3:1), supplemented with
10% fetal bovine serum (FBS), 2 mM glutamine (Sigma), 25 ng/ml fibro-
blast growth factor (FGF2), 10 ng/ml epidermal growth factor (EGF)
(Becton Dickinson), and antibiotics/antimycotics (Life Technologies).
Seeded on 75-cm2 cell culture flasks (Nunc), the first medium change
was made 10–14 days later when the colonies of adherent cellsappeared; non-adherent cell debris was removed by changing the me-
dium. Next, CSF cell cultures were trypsinized and again plated until
the cultures reached 60%–70% confluence. Finally, cells were harvested
using trypsin and seeded: in 60-mm culture dishes for RNA extraction
and RT-PCR analysis, or onto cover slips on 12-well plates for
immunocytofluorescence analysis. All experiments were performed on
cells between passages 1 and 2.2.3. Cell proliferation assay
Human CSF-derived primary cultured cells were seeded at 75,000
cells/well in 24-well culture plates and incubatedwith proliferatingme-
dium, which was changed every 2–3 days. Quadruplicate wells were
counted at days 3 and 5 using a Neubauer chamber.2.4. Immunocytofluorescence analysis
For immunocytofluorescence analysis, cells were fixedwith 4% para-
formaldehyde for 30 min at room temperature, washed three times
with phosphate-buffered saline (PBS, Life Technologies), incubated for
20 min with 0.1% triton X-100 in PBS with agitation, and blocked with
PBS with 3% bovine serum albumin (BSA, Sigma) for 30 min before an-
tibody incubation. Primary antibodies against TBR2 (ab23345, Abcam),
CD15 (ab119844, Abcam), SOX2 (ab97959, Abcam), βIII-tubulin
(ab41489, Abcam), GFAP (Z0334, Dako), Oligo-O1 (MAB5540,
Chemicon) and CNPase (ab6319, Abcam) were diluted 1:100 in PBS
with 1% BSA and incubated in a humid chamber for 16 h at 4 °C. Next,
cover slips were washed three times with PBS and incubated with the
secondary antibodies diluted 1:1000 in PBS with 1% BSA containing 1
μg/ml Hoechst 33,342 (Invitrogen) in a dark humid chamber for
45 min at room temperature. Secondary antibodies used for single or
triple immunocytofluorescence analysis were the Alexa Fluor® 568
anti-mouse (A-11004, Invitrogen), Alexa Fluor® 488 anti-rabbit (A-
11008, Invitrogen), Alexa Fluor® 488 anti-mouse (A-11001,
Invitrogen), Alexa Fluor® 647 anti-rabbit (A-21245, Invitrogen), Alexa
Fluor® 647 anti-chicken (A-21449, Invitrogen), and Alexa Fluor® 568
anti-chicken (A-11041, Invitrogen). Finally, cover slips were washed
three times with PBS and mounted with Fluoromount-G mountingme-
dium (Southern Biotech). Microphotographs were obtained by using a
BX-61 microscope (Olympus).2.5. Analysis of gene expression by quantitative real-time PCR
Human CSF-derived NPCs were cultured on 60-mm dishes. When
confluence reached 50%–60%, total RNA was extracted using TRIzol
(GIBCO BRL Life Technologies) and purified on RNeasy Micro kit col-
umns (Qiagen, Hilden, Germany). Reverse-transcriptase (RT) reaction
was performed using up to 5 μg of total RNA with the Superscript II RT
kit (Invitrogen, Carlsbad, CA) following themanufacturer's instructions;
to each RT reaction, we added 100 ng of Random primers (Promega,
Southampton, UK) and 20 units of SUPERase-in RNase inhibitor
(Ambion, Huntingdon, UK) to prevent RNA degradation.
The gene expression levels of CD15, TBR2 and SOX2 were analyzed
by quantitative real-time PCR. Each data point was normalized by the
mRNA abundance of the housekeeping PES1 control gene. All oligonu-
cleotide primer pairs used for each gene in this study (Supplementary
Table 1) were designed according to the sequences derived from
GenBank (accession numbers in parenthesis). Complementary DNA
(25 ng) from the RT reaction was used as a template for each PCR in a
10-μl reaction volume. All qRT-PCR reactions were performed using
the LightCycler® 480 SYBR Green I Master kit and a LightCycler® 480
II Thermocycler (Roche, Indianapolis, IN) following the manufacturer's
instructions.
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subtypes by growth factors deprivation
CSF-derived cells (105 cells/well) were seeded onto cover slips on
12-well plates and cultured with proliferation medium (DMEM:M-
199 medium, 3:1, supplemented with 10% FBS, 2 mM glutamine
(Sigma), 25 ng/ml fibroblast growth factor (FGF2), 10 ng/ml epidermal
growth factor (EGF) (Becton Dickinson), and antibiotics/antimycotics
(Life Technologies) until the confluence reached 40%–50%. Cells were
then washed twice with PBS and induced to arbitrary differentiation
into neural lineage cell subtypes by incubation for 10 days with
StemPro®NSC SFMmedium(Life Technologies) in the absence of exter-
nal growth factors addition. Cell culture mediumwas replaced every 2–
3 days.
2.7. Specific differentiation of CSF-derived NPCs into neural lineage cell
subtypes
CSF-derivedNPCswere plated onto cover slips on 12-well plates and
cultured. When the confluence reached 40%–50%, cultures were in-
duced to differentiate into three neural lineage cell types as neurons, as-
trocytes, or oligodendrocytes by incubating with explicit differentiation
mediums as follows:
2.7.1. Neuron-specific differentiation protocol
NPCswere plated onto polyornithine and laminin-coated cover slips
on 12-well plates before cell seeding. Cover slips in culture vessels were
incubated with 20 μg/ml poly-L-ornithine (P3655, Sigma) solution for
1 h at 37 °C, rinsed twice with sterile water, incubated with 10 μg/ml
laminin (Life Technologies) solution for 2 h at 37 °C, and rinsed with
PBS without calcium or magnesium (Life Technologies). The cells (105
cells/well) were then seeded and cultured with proliferation medium
(DMEM:M-199medium, 3:1, supplemented with 10% FBS, 2 mM gluta-
mine (Sigma), 25 ng/ml fibroblast growth factor (FGF2), 10 ng/ml epi-
dermal growth factor (EGF) (Becton Dickinson), and antibiotics/
antimycotics (Life Technologies). When the confluence reached 40%–
50%, cells were washed twice with PBS before incubation with differen-
tiation medium.Fig. 1.Human cerebrospinalfluid (CSF) collection during the prenatal surgical repair ofmyelom
infraumbilical laparotomy and hysterotomy in the pregnant mother (b), the fetal lumbar re
immediately used to establish CSF-derived primary cell cultures. Scale bars = 200 μm.Differentiation into neurons was induced by incubating for 7 days
with neural differentiation medium composed of Neurobasal Medium
with 2% of B-27 Serum-Free supplement, 2mMGlutaMAX-I, and antibi-
otic-antimycotic solution (all from Life Technologies). At day 7,
dibutyryl cAMP (Sigma)was added to themedium, to reach a final con-
centration of 0.5mM, and incubated up to day 10. Differentiationmedi-
um was replaced every 2–3 days.
2.7.2. Astrocyte-specific differentiation protocol
NPCs were plated onto Geltrex-coated cover slips on 12-well plates.
Before cell seeding, cover slips in culture vessels were incubated with
Geltrex (P3655, Sigma) working solution (diluted 1:200 with DMEM/
F-12 followingmanufacturer's instructions) for 1 h at room temperature
and washed once with D-PBS with calcium and magnesium (Life Tech-
nologies). Cells (105 cells/well) were seeded and cultured with prolifer-
ation medium (DMEM:M-199 medium, 3:1, supplemented with 10%
FBS, 2 mM glutamine (Sigma), 25 ng/ml fibroblast growth factor
(FGF2), 10 ng/ml epidermal growth factor (EGF) (Becton Dickinson),
and antibiotics/antimycotics (Life Technologies). When the confluence
reached 40%–50%, cells were then washed twice with PBS before incu-
bation with differentiation medium.
Differentiation into astrocytes was induced by incubating with as-
trocyte-differentiation medium composed of DMEM with 1% of N-2
supplement, 2 mM GlutaMAX-I, 1% FBS, and antibiotic-antimycotic so-
lution (all from Life Technologies) for 10 days. Differentiation medium
was replaced every 2–3 days.
2.7.3. Oligodendrocyte-specific differentiation protocol
NPCswere plated onto polyornithine and laminin-coated cover slips
on 12-well plates before cell seeding as above. Then, cells (105 cells/
well) were seeded and cultured with proliferating medium
(DMEM:M-199 medium, 3:1), supplemented with 10% FBS, 2 mM glu-
tamine (Sigma), 25 ng/ml fibroblast growth factor (FGF2), 10 ng/ml epi-
dermal growth factor (EGF) (Becton Dickinson), and antibiotics/
antimycotics (Life Technologies) until the confluence reached 40%–
50%. Cells were washed twice with PBS before incubationwith differen-
tiation medium.eningoceles (MMC). (A) CSF collected from the cysts over the defect (a) before repair. After
gion was exposed (c). (B) CSF samples were gently aspirated with a sterile syringe and
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with oligodendrocyte-specific differentiation medium for 10 days. It
contained Neurobasalmediumwith 2% of B-27 Serum-Free supplement
(Life Technologies), 2 mM GlutaMAX-I (Life Technologies), 30 ng/ml
Triiodo-L-Thyronine (T3, Sigma), and antibiotic-antimycotic solution
(Life Technologies). Differentiation medium was replaced every 2–
3 days.
2.8. Flow cytometry
Cells were dissociatedwith Tripsin 0.25% (Life Technologies) and re-
suspended in stain buffer (BD Pharmingen) by adding 5mMEDTA. Cells
were stained live on ice for 20 min with a specific antibodies panel as
previously reported by Yuan SH et al. (Yuan et al., 2011). Cells were
washed and NSC/NPC (CD45−/CD184+/CD44−/CD271−/CD24+/
CD15+), neurons (CD45−/CD184−/CD44−/CD24+/CD15Low), and
glia cell (CD45−/CD184+/CD44+/CD271−) populations were ana-
lyzed by flow cytometry on a LSRII Flow Cytometer system (BD
Pharmingen). All fluorochrome-conjugated antibodies were from BD
or BioLegend unless otherwise noted: Fixable viability staining
(eBioscience), CD45 (557059), CD184 (306516), CD271 (345110),Fig. 2. Human CSF-derived primary cell cultures from MMC patients. (A) Human CSF-derived c
primary culture. Scale bars= 200 μm. (B) Primary cultured cells were seeded at 75,000 cells/w
were counted on days 3 and 5. Values mean ± standard deviation (SD). * indicates p b 0.05 anCD44 (103043), CD24 (555427) and CD15 (125614). Data were ana-
lyzed by BD FACSDiva™ (BD Pharmingen) software for generation of
heat maps.
2.9. Statistical analysis
For immunocytofluorescence images, the average signal intensity
was calculated as: normalized mean signal intensity to exposure time
divided by number of nuclei. Signal intensities and nuclei count obtain-
ed using Image J software (version 1.45s; NIH, Bethesda, MD), averag-
ing 3 or 4 images. Student's t-test was used to determine statistical
significance throughout the study. Differences were considered signifi-
cant with a p value b 0.05. Data are presented as mean ± standard de-
viation (SD).
3. Results
By successful extraction of CSF samples from the cyst of the
myelomeningocele during fetal surgery at mid gestation (Fig. 1), our
protocol detected the presence of NPCs in CSF-derived primary culture
by the expression of neural and pluripotent specific markers TBR2,ells from 6 fetal patients aged 20 to 26 weeks of gestation were successfully expanded in
ell in 24-well culture plates and incubatedwith proliferatingmedium. Quadruplicate wells
d ** indicates p b 0.01 respecting cell number at time 0. CSF, cerebrospinal fluid.
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PCR, and flow cytometry analysis.
3.1. Establishment of primary cell cultures from human MMC patients CSF
samples
From the CSF samples extracted from 6 fetuses, CSF-derived cells
were successfully grown in primary culture (Fig. 2A). Proliferation
rates at day 3 and 5 (Fig. 2B) exhibited linear growth. Compared with
baseline day 0, cell numbers increased 335 ± 44% (p = 0.026) and
547 ± 125% (p= 0.0027) at days 3 and 5, respectively.
3.2. Human CSF-derived primary cultured cells show neural progenitor cell
characteristics
To determine the presence of NPCs in CSF-derived primary culture,
we studied the expression of the neural and pluripotent specific
markers TBR2 (Hodge et al., 2012; Hodge et al., 2008), SOX2 (Pevny
and Nicolis, 2010; Tanaka et al., 2004; Wegner and Stolt, 2005; Wells
et al., 2011), and CD15 (Capela and Temple, 2002; Doetsch, 2003;
Dromard et al., 2008) by immunocytofluorescence and quantitative
real-time PCR analysis. CSF-derived cultured cells showed robust ex-
pression of the specific neural progenitor markers CD15, SOX2, and
TBR2 (Fig. 3A); specifically, percentages of positive cells were 45.4 ±
5.4%, 27.6 ± 7.8% and 31.3 ± 4.2%, respectively (Fig. 3B). qPCR analysisFig. 3. NPC markers expression in MMC patient's CSF-derived primary cultured cells. Anal
demonstrated positive staining of the NPCs markers CD15, SOX2 and TBR2 in CSF-derived cell
for CD15, SOX2, and TBR2 markers defined as total number of cells in CSF-derived cell cult
normalized by the PES1 mRNA content. Data means ± SD obtained from 3 independent expe
CD15, 3-fucosyl-N-acetyl-lactosamine; SOX2, SRY (Sex Determining Region Y)-Box 2; TBR
biogenesis factor 1.demonstrated the presence of NPC markers expression in CSF-derived
primary cultured cells (Fig. 3C). Compared with control gene PES1,
mRNA abundance for the genes CD15, SOX2, and TBR2 was 0.72 ±
0.16, 0.73 ± 0.27, and 0.46 ± 0.15 (based on relative expression
units), respectively. Thus, a cell subpopulation with neural progenitor
characteristics was found in the CSF of myelomeningocele fetuses dur-
ing the course of the disease.3.3. In vitro random differentiation of CSF-derived NPCs into neural lineage
cell subtypes
CSF-derived NPCs in primary culture were induced to differentiate
by growth factor deprivation to determine their arbitrary capacity to
differentiate into neural lineage cell subtypes. In primary cultured cells
at a confluence of 40–50% incubated for 10 days with the StemPro®
NSC SFMmedium in the absence of growth factors, human CSF-derived
NPCs had a strong capacity to differentiate into neural lineage cells as
neurons, astrocytes, and oligodendrocytes. This was demonstrated by
the expression of the neuronal (βIII-tubulin) and glial (GFAP for astro-
cytes, CNPase and oligo-O1 for oligodendrocytes) specific markers,
whichwere detected by triple immunocytofluorescence after differenti-
ation (Fig. 4). Cells weremonitored for morphological changes (Fig. 4A)
and expression changes in specific neural lineage markers (Fig. 4B).
Cells induced to differentiate with StemPro®NSC SFMmediumwithoutysis by immunocytofluorescence and real-time RT-PCR. (A) Immunocytofluorescence
s. Cell cultures from CSF-fc1 patient. Scale bars = 200 μm. (B) Percentage of positive cells
ures. (C) qPCR values of CD15, SOX2, and TBR2 mRNA abundance were quantified and
riments. NPC, neural precursor cell; CSF, cerebrospinal fluid; MMC, myelomeningocele;
2, T-box transcription factor Eomes/T-box brain protein 2; PES1, Pescadillo ribosomal
Fig. 4. Arbitrary neural differentiation of human CSF-derived cells in primary culture. CSF-derived cells seeded onto cover slips on 12-well plates and cultured by incubation with
proliferation medium. When confluence reached 40%–50%, cells then induced to differentiate by deprivation of growth factors by incubating with StemPro® NSC SFMmedium without
addition of EGF and bFGF growth factors for 10 days. Neural differentiation analyzed by morphological changes monitored under optical microscopy (A) or by expression of specific
neural differentiation markers GFAP (glial marker), βIII-tubulin (neuronal marker) and CNPase (oligodendrocyte marker) determined by triple immunocytofluorescence (B). β3Tub+/
GFAP- (light blue arrow) and CNPase+/GFAP- cells (yellow arrow). Microphotographs of 10-day differentiated CSF-derived cells from CSF-fc1 patient. Scale bars = 200 μm. CSF,
cerebrospinal fluid; EGF, epidermal growth factor; bFGF, basic fibroblast growth factor; GFAP, glial fibrillary acidic protein; βIII-tubulin, class III β-tubulin; CNPase, 2′,3′-Cyclic-
nucleotide 3′-phosphodiesterase.
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sions and abundant neurites or large rounded cell bodies).
3.4. In vitro specific differentiation into neural lineage cell subtypes of
CSF-derived NPCs
In evaluating CSF-derived NPCs differentiation into neurons, astro-
cytes, or oligodendrocytes during a 10-day incubation with specific dif-
ferentiation mediums, NPCs effectively differentiated into the three
neural lineages. Specific morphological changes identified included
spindle shape with growing neurite protuberances for neurons and oli-
godendrocytes; and round-flat shape for astrocytes. The expression
of specific markers for neuron (βIII-tubulin), astrocyte (GFAP),
and oligodendrocyte (oligo-O1) lineages was noted in triple
immunocytofluorescence (Fig. 5). When compared with CSF-derived
proliferating cells, cells differentiated into neurons showed a robust
5.7-fold increase (p = 0.014) in the neuronal marker βIII-tubulin
(Fig. 6A) and clear expression of the neuronal markersMAP2 and nestin
(Supplementary Fig. 1). Astrocyte-specific differentiation of CSF-
derived NPCs induced the strongest upregulation (8.6-fold) of the
GFAP astrocyte marker (p= 0.0022) (Fig. 6B) and lesser increased ex-
pression of the neuronal and oligodendrocyte markers βIII-tubulin
(2.3-fold, p=0.0017) and oligo-O1 (6.5-fold, p=0.0057). Additionally,
oligodendrocyte-specific differentiation induced the strongest 12.1-fold
upregulation of the oligodendrocyte marker oligo-O1 (p = 2.0e-4);
increases of the βIII-tubulin (5.2-fold, p= 2.5e-5) and GFAP (5.3-fold,p = 0.0017) markers were also detected following the specific oligo-
dendrocyte differentiation process (Fig. 6C).
3.5. Flow cytometry evaluation of CSF-derived cell populations
We used a previously described (Yuan et al., 2011) flow cytometry
strategy to corroborate the presence of NSC/NPC, neuronal and glial
cell populations in CSF-derived primary cultured cells (Fig. 7). Cells
were first selected on the basis of viability staining and the absence of
CD45 staining. NSC/NPC cell populations were selected for CD184+
and then negative selected for CD44- and CD271- and co-expression
of CD24+ and CD15+. The percentage of CD184+/CD271−/CD44−/
CD24+/CD15+ cells in CSF-derived cell cultures was 1.4% of total.
However, glial cells were selected for CD184+ and then for CD44+
and CD271−, which represented the 0.1% of total CSF-derived cells.
Cells committed to the neuronal lineagewere first selected for depletion
of CD44 and CD184 and then for CD24+ and CD15low staining. Thus,
neuronal population (CD184−/CD44−/CD15Low/CD24+) represent-
ed the 0.3% of the total CD45- and live cells.
4. Discussion
Our novel approach for potential cell therapy used a previously
uncharacterized class of progenitor cells extracted during in utero repair
of myelomeningocele. With successful extraction of NPCs from the CSF
of myelomeningocele's cyst in midgestation fetuses, the cells
GFAP
Neuron











Fig. 5. Specific differentiation of CSF-derived NPCs into neural lineage cell subtypes. CSF-derived cells were seeded onto cover slips on 12-well and cultured by incubation with proliferation
medium. When confluence reached 40%–50%, cells were induced to differentiate into the three neural lineage cell types, neurons, astrocytes and oligodendrocytes, by incubating with
specific differentiation mediums for 10 days. Expression of the neural differentiation markers GFAP (astrocyte marker), βIII-tubulin (neuron marker) and Oligo-O1 (oligodendrocyte marker)
was determined by triple immunocytofluorescence before (proliferating cells) and after (differentiated cells) the 10-days differentiation period. Pictures show representative images of cell
cultures from CSF-fc3 patient. Scale bars = 100 μm. CSF, cerebrospinal fluid; GFAP, glial fibrillary acidic protein; βIII-tubulin, class III β-tubulin; Oligo-O1, oligodendrocyte marker O1.
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Fig. 6.Neuronal, astrocyte and oligodendrocyte differentiation of CSF-derived NPCs alters
markers expression. Relative expression of βIII-tubulin (A), GFAP (B) or oligo-O1 (C) as
neuronal, astrocyte and oligodendrocyte differentiation markers, respectively, was
analyzed by qPCR in CSF-derived cells before (light gray bars) or after (dark gray bars)
10-days of random or specific differentiation into neuronal, astrocyte or oligodendrocyte
lineage cells. Relative expression is shown as the average signal intensity graphs from
the images obtained by immunocytofluorescence analysis. Error bars = SD, *p b 0.05,
**p b 0.01, ***p b 0.001.
40 M. Marotta et al. / Stem Cell Research 22 (2017) 33–42proliferated in vitro and had the ability to differentiate into neuronal
and glial cells, specifically neurons, astrocytes, or oligodendrocytes.
Their differentiation into various neural lineage cell subtypes along
with morphological changes and expression for specific markers may
further the development of new therapeutics based on NPCs for spinal
cord repair, such as autologous cell transplantation in spina bifida pa-
tients. Cell therapy-based approaches could be particularly interesting
because of the current limitations of prenatal surgical treatment of
myelomeningocele in restoring neural damage or preventing further
damage to the spinal cord pre- or post-natal.
4.1. Human CSF-derived NPCs expansion and neurogenic properties
The presence of neural stem and progenitor cells have been found in
adult spinal cord tissuein animal models (Shihabuddin et al., 1997;
Weiss et al., 1996) and humans (Dromard et al., 2008). Spinal-cord-
derived cells have the ability to proliferate in vitro and differentiate
into neurons and glial cells (Dromard et al., 2008). Demonstrating a
high neurogenic potential in vitro, these multipotent cells could repre-
sent an excellent resource in the development of new therapeutic ap-
proaches for repair of spinal cord injury. The presence of neural stem
and progenitor cells in adult human spinal cords suggests the possibility
for their potential migration or liberation into the circulating CSF across
the central canal. Thus, these cells could be isolated and expanded in
culture for use in therapeutic approaches to spinal cord tissue repair.
In myelomeningocele disease, development of new prenatal thera-
peutic approaches for repair of spinal cord injury using autologous cell
transplantation during gestation becomes possible based on the ability
to isolate a cell population with neurogenic properties from fetal CSF.
In this scenario, the progenitor cells needed to regenerate damaged spi-
nal cord tissue could be obtained from each patient and developed as a
personalized cell-therapy-based treatment.
Despite considerable research directed to localize neurogenic cells in
the adult spinal cord (Dromard et al., 2008; Shihabuddin et al., 1997;
Weiss et al., 1996), fewpublicationshave addressed the presence of plu-
ripotent cells in human fetal CSF. A 2006 study revealed the presence of
NPCs in CSF samples of preterm patients with post-hemorrhagic hydro-
cephalus (Krueger et al., 2006), suggesting the potential of human pre-
term CSF as a source of NPCs.
After confirming the presence of NPCs in CSF samples collected from
the lumbosacral cysts ofmyelomeningoceles in fetuses, we showed that
these cells had the ability to proliferate in vitro and to differentiate into
neuronal and glial cells. These findings then suggest the possibility of in
vivo differentiation. Cell culture of neural precursor cells from human
fluids requires the use of fresh and well-preserved samples, which
pose a technical challenge in obtaining fetal samples during gestation.
We overcame this obstacle by extracting the CSF during prenatal
surgery, specifically from the lumbar cyst surrounding the
myelomeningocele defect (Fig. 1). Eventually, collection of fetal CSF in
this clinical scenario could be by ultrasound-guided tap of the
myelomeningocele cyst during the amniocentesis procedure, weeks be-
fore the prenatal myelomeningocele intervention. This technique could
ensure sufficient time for cell culture, expansion of the NPCs before pre-
or post-natal surgical repair, and finally autologous NPCs transplanta-
tion for spinal cord repair.
Previous studies have shown that embryonic CSF contains both neu-
rogenic growth factors (Buddensiek et al., 2010; Zappaterra and
Lehtinen, 2012) and some circulating cells with neural progenitor prop-
erties (Krueger et al., 2006). Despite low cellularity (de Graaf et al.,
2011), we successfully established primary cultures with small
extractions of 1.5–2 ml of CSF fluid from the cyst of the fetal
myelomeningoceles (Fig. 2). Our flow citometry results of fresh CSF
samples showed clearly its low cellularity, and the need for primary cul-
ture expansion to achieve relevant numbers of NPCs.
Once expanded in culture, the expression of specific NPC markers
(i.e., TBR2, SOX2, CD15) was corroborated to show the potentialneurogenic properties of CSF-derived primary cultured cells (Fig. 3).
TBR2, SOX2, and CD15 are well known NPC markers that have been
expressed in neural stem/progenitor cells. Specifically, TBR2, a marker
of intermediate neuronal progenitors, plays a key role driving the pro-
gression from neural stem cells to intermediate progenitors and neu-
rons (Hodge et al., 2012; Hodge et al., 2008). SOX2, a neural stem cell
pluripotency marker (Pevny and Nicolis, 2010; Tanaka et al., 2004;
Wells et al., 2011), is directly involved in the maintenance of adult
and embryonic neural progenitor and stem cells (Wegner and Stolt,
2005). CD15 (SSEA-1), a marker of neural stem cells (Capela and
Temple, 2002; Doetsch, 2003), is also detected in the immature neural
precursor cells and heterogeneously expressed by a large fraction of
Fig. 7. Flow Cytometry analysis of cell populations in CSF-derived primary cultured cells. Human CSF-derived cells from cystic MMC fetal patients were expanded in primary culture and
used for cell population analysis by flow cytometry. (A) Cells were first selected base on Viability Staining and CD45. NSC/NPC were selected for CD184+ and then negative selected for
CD44− and CD271− and co-expression of CD24+ and CD15+. Glial cells were selected for CD184+ and then for CD44+ and CD271−. (B) Neuronal population was first selected for
depletion of CD44− and CD184− and for CD24+ and CD15low.
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Our findings of CD15, SOX2, and TBR2 expression correlated with
previous studies that described N90% of SOX2(+) and 35–55% of
CD15(+) cells in lumbar samples of adult human spinal cords
(Dromard et al., 2008). Their presence in CSF-circulating cells suggest
their possible origin by migration from the cell layer along the central
canal in human spinal cord (Brill et al., 2009; Dromard et al., 2008).
However, more research is needed to define their possible origins
(e.g., ependymal, subependymal, and subventricular zones or choroid
plexus).4.2. Human CSF-derived NPCs multi-lineage capacity
In confirming human CSF-derived NPCs multipotency, our analysis
included the neurogenic properties of primary cultured cells from the
fetalmyelomeningocele cysts. Inducing in vitro differentiation into neu-
ral and glial cell subtypes demonstrated their strong potential to differ-
entiate into neurons, astrocytes and oligodendrocytes either by random
differentiation in the absence of growth factors (Fig. 4) or by specific dif-
ferentiation (Fig. 5).
Myelomeningoceles CSF-derived cells not only generated a large
number of differentiated cells with characteristic neural cell morphol-
ogies (spindle shaped with growing neurite protuberances for neurons
and oligodendrocytes, and round-flattened for astrocytes) but strongly
expressed specific differentiation markers for neuronal (βIII-tubulin),
astrocyte (GFAP), and oligodendrocyte (CNPase, oligo-O1) cell lineages
(Fig. 6). Our findings showing the neurogenic properties of fetal CSF-
derived cells from the cystic myelomeningocele defect confirms previ-
ous in vitro findings for human neural stem/precursor cells from various
origins (Barnabé-Heider and Frisén, 2008; Li and Lepski, 2013; Mothe
and Tator, 2013; Parati et al., 2004; Sandner et al., 2012).5. Conclusion
To the best of our knowledge, our findings provide the first evidence
of NPCs present in the CSF of the lumbar cyst of myelomeningocele-af-
fected fetuses. The effective expansion of CSF-derived cells in primary
culture and their differentiation into neuronal and glial cells suggests
their potential for future therapeutic approaches in spinal cord regener-
ation. Thus, our findings could help in the development of innovative
progenitor/stem cell-based therapies for the regeneration of damaged
neural tissue by usingNPCs obtained from the patient's own CSF sample
and later autologous cell transplantation in the injured spinal cord. Fur-
ther studies in myelomeningocele animal models will analyze in vivo
ability to colonize, integrate, and restore the damaged neural tissue, as
well as to promote regeneration at the spinal cord level. Future studies
will ultimately develop new fetal or postnatal therapeutic approaches
for myelomeningocele patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2017.05.003.
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